Assessing Mirum Pharmaceuticals (MIRM) Valuation After Strong Shareholder Returns And Rare Disease Pipeline Progress [Yahoo! Finance]
Mirum Pharmaceuticals, Inc. - common stock (MIRM)
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Mirum Pharmaceuticals (MIRM) has been drawing attention after posting annual revenue of US$521.3 million and a net loss of US$23.4 million, putting its rare disease portfolio and recent share performance under closer investor review. See our latest analysis for Mirum Pharmaceuticals. Mirum's recent annual numbers arrive after a strong year for shareholders, with a 116.34% 1 year total shareholder return, even as the 90 day share price return of 8.67% suggests momentum has cooled slightly in the short term. If Mirum's rare disease focus has your attention, this can be a good moment to scan for other specialised healthcare names using our screener of 32 healthcare AI stocks With Mirum trading at US$94.00 against an analyst price target of US$129.27 and an intrinsic value estimate suggesting a sizeable discount, the question is whether there is still a buying opportunity here or whether the market is already pricing in future growth. Most Popular Narrative: 11.8% Undervalued
Show less
Read more
Impact Snapshot
Event Time:
MIRM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIRM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
News
- Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026Business Wire
- Mirum Pharmaceuticals (MIRM) had its price target raised by Stifel Nicolaus from $125.00 to $130.00. They now have a "buy" rating on the stock.MarketBeat
- Mirum HDV Trial Success Adds New Late Stage Growth Option [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals (MIRM) had its price target raised by Robert W. Baird from $95.00 to $112.00. They now have an "outperform" rating on the stock.MarketBeat
- Mirum Pharmaceuticals (MIRM) had its "buy" rating reaffirmed by HC Wainwright.MarketBeat
MIRM
Earnings
- 2/25/26 - Miss
MIRM
Sec Filings
- 4/27/26 - Form SCHEDULE
- 4/27/26 - Form 8-K
- 4/24/26 - Form ARS
- MIRM's page on the SEC website